Plain-English translation of NCT07071649 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are testing whether a new blood marker called p-Tau217 can accurately detect Alzheimer's disease. Right now, doctors diagnose Alzheimer's by analyzing fluid from the spine, which requires a procedure called a lumbar puncture. This study wants to see if measuring p-Tau217 in a simple blood draw could work just as well.
A blood test would be much easier and less invasive than a spinal tap for patients and doctors. If this new blood marker works as well as the current spinal fluid tests, it could help diagnose Alzheimer's disease faster and make screening more accessible to more people.
You likely qualify if…
You likely don't qualify if…
You will come to the hospital for a scheduled lumbar puncture to collect spinal fluid, which is the standard test your doctor ordered. At the same time, a single tube of blood will be drawn from your arm for the new p-Tau217 test. The whole study takes about 18 months, and you'll be compared with other patients in the study to see how well the blood test matches the spinal fluid results.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment target
~40 participants
Started
November 2025
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pia-Manuela Rusu, MD
Centre Hospitalier Universitaire, Amiens
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.